China has censored DXY, the country’s leading health information platform. On August 9, DXY fell silent across social media, where it boasts over 80 million followers. Five of its Weibo accounts were suddenly suspended with a vague explanation that they had violated “relevant laws and regulations,” while its accounts on WeChat and Douyin (the domestic version of TikTok) stopped publishing.
Neither these social media platforms nor DXY have released any public statement on what caused the suspension, but Nikkei Asia reported that the order came from regulators and won’t end without official approval.
The suspension has met with a gleeful social reaction among nationalist bloggers, who accuse DXY of receiving foreign funding, bashing traditional Chinese medicine, and criticizing China’s health-care system.
DXY is one of the front-runners in China’s digital health startup scene. It hosts the largest online community Chinese doctors use to discuss professional topics and socialize. It also provides a medical news service for a general audience, and it is widely seen as the most influential popular science publication in health care.
“I think no one, as long as they are somewhat related to the medical profession, doesn’t follow these accounts [of DXY],” says Zhao Yingxi, a global health researcher and PhD candidate at Oxford University, who says he followed DXY’s accounts on WeChat too.
But in the increasingly polarized social media environment in China, health care is becoming a target for controversy. The swift conclusion that DXY’s demise was triggered by its foreign ties and critical work illustrates how politicized health topics have become.
Since its launch in 2000, DXY has raised five rounds of funding from prominent companies like Tencent and venture capital firms. But even that commercial success has caused it trouble this week. One of its major investors, Trustbridge Partners, raises funds from sources like Columbia University’s endowments and Singapore’s state holding company Temasek. After DXY’s accounts were suspended, bloggers used that fact to try to back up their claim that DXY has been under foreign influence all along.
Part of the reason the suspension is so shocking is that DXY is widely seen as one of the most trusted online sources for health education in China. During the early days of the covid-19 pandemic, it compiled case numbers and published a case map that was updated every day, becoming the go-to source for Chinese people seeking to follow covid trends in the country. DXY also made its name by taking down several high-profile fraudulent health products in China.
It also hasn’t shied away from sensitive issues. For example, on the International Day Against Homophobia, Transphobia, and Biphobia in 2019, it published the accounts of several victims of conversion therapy and argued that the practice is not backed by medical consensus.
“The article put survivors’ voices front and center and didn’t tiptoe around the disturbing reality that conversion therapy is still prevalent and even pushed by highly ranked public hospitals and academics,” says Darius Longarino, a senior fellow at Yale Law School’s Paul Tsai China Center.
The sudden suspension of DXY’s social media accounts caught its followers by surprise. “I don’t think they have done anything improper,” says Zhao.
But opponents of DXY were quick to find a political explanation. On social media, some defended the suspension on the basis that DXY has questioned the efficacy of traditional Chinese medicine (TCM.)
In April 2022, DXY published an article about Lianhua Qingwen, a modern TCM product that has been distributed by the Chinese government as a treatment for covid-19. In the now-deleted article, the DXY authors cautioned that the medicine has never been properly tested in a clinical trial, and pointed out that some of the ingredients are banned in other countries.
The article, widely read and circulated, caused the value of the pharmaceutical company behind Lianhua Qingwen, Shijiazhuang Yiling Pharmaceutical, to fall by $1.05 billion on the stock market. To most health-care professionals, the article was reasonable and uncontroversial. But it made DXY a target for TCM supporters. Since then, DXY has been accused of colluding with Western pharmaceutical companies like Pfizer, which manufactures the covid-19 treatment Paxlovid, to defame TCM. TCM supporters celebrated the suspension of DXY’s accounts as proof of the platform’s wrongdoings.
Just as in the US, certain public health topics have become heavily politicized in China, including covid-19. Choosing a side in scientific debates in China is oftentimes equated to choosing a side in the ideological divide between China and the West.
Although DXY is the most prominent example, it’s not the first popular science publication to fall victim to social media campaigns in China. Several popular digital science publications and video channels, like Elephant Magazine and Paperclip, have been trolled and targeted by nationalist influencers for receiving funding from foreign NGOs and publishing content that paints China in a bad light. These publications either dissolved or disappeared from social media after they were censored.
DXY’s supporters fear it could go the same way.
“This is the best domestic health education platform. It has contributed greatly to the popularization of evidence-based medicine,” Wang Zhian, a Chinese journalist whose social media accounts were censored in 2019 before he emigrated to Japan, wrote on Twitter. “I hope it can survive.”
What’s next for AI regulation in 2024?
The coming year is going to see the first sweeping AI laws enter into force, with global efforts to hold tech companies accountable.
Three technology trends shaping 2024’s elections
The biggest story of this year will be elections in the US and all around the globe
Four lessons from 2023 that tell us where AI regulation is going
What we should expect in the coming 12 months in AI policy
The FTC’s unprecedented move against data brokers, explained
It could signal more aggressive action from policy makers to curb the corrosive effects that data brokers have on personal privacy.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.